This is a 1-month, prospective, multicenter, open-label study in pediatric subjects with bilateral middle ear effusion requiring tympanostomy tube placement. Eligible subjects will receive a single dose to each ear of 6 mg OTO-201, administered intraoperatively into the middle ear through the lumen of the tympanostomy tube (trans-tympanostomy tube TTT). The study is designed to characterize safety and any procedural issues associated with TTT drug administration of OTO-201.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
33
Central California Ear, Nose and Throat
Fresno, California, United States
Charlotte Eye, Ear, Nose and Throat Associates
Charlotte, North Carolina, United States
Charlotte Eye, Ear, Nose and Throat Associates
Matthews, North Carolina, United States
Piedmont Ear, Nose and Throat
Winston-Salem, North Carolina, United States
Otoscopic Examination: Auricle and Meatus
Number of ears whose external ear and ear canal (auricle and meatus), when examined through an otoscope, appeared normal at Baseline and appeared abnormal at Day 29
Time frame: Up to 1 month
Otoscopic Examination: Tympanic Membrane
Number of ears whose ear drum (tympanic membrane), when examined through an otoscope, appeared normal at Baseline and appeared abnormal at Day 29
Time frame: up to 1 month
Otoscopic Examination: Tube Patency
Subjects with at least one ear tube patent (i.e., not blocked) at Day 29
Time frame: Up to 1 month
Feasibility of Administration
Ease of administering OTO-201 through the tympanostomy tube: Number of subjects that investigators rated ease of administration as either "easy" or "very easy"
Time frame: Day 1
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Carolina Ear, Nose and Throat
Orangeburg, South Carolina, United States